- Home
- AUTL vs FTHY Comparison
AUTL vs FTHY Comparison
Compare AUTL & FTHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUTL | FTHY |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 516.7M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUTL | FTHY |
|---|---|---|
| Price | $1.69 | $13.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 82.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.93% |
| EPS Growth | ★ 28.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $670.78 | N/A |
| Revenue Next Year | $80.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $12.84 |
| 52 Week High | $2.70 | $14.98 |
Technical Indicators
Market Signals| Indicator | AUTL | FTHY |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 30.86 |
| Support Level | $1.65 | N/A |
| Resistance Level | $1.69 | $14.24 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 51.99 | 16.35 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.